Valuing medical device companies for mergers and acquisitions remains a critical, yet challenging process. The market is shaped by rapid innovation, shifts in reimbursement, advanced regulatory frameworks, and an investor ecosystem that prizes both growth and resilience. The Enterprise Value to Forward Sales (EV/Sales) multiple remains a key metric, but it is most effectively used as part of a broader, dynamic framework.
Key Determinants of Valuation
1.Supernormal Revenue Growth
2. Market Size & Sector Growth
3. Competitive Positioning
4. Venture and Public Market Validation
5. Regulatory Status and Clarity
6. Potential Profit Margin
7. Synergy and Platform Fit
Table 1: Key Variables Influencing Medical Device M&A Valuation (EV/Sales Multiples)
Table 2: Recent Major Medical Device M&A Transactions (2020-2025)
Sources: Company press releases, S&P Global, Mergermarket, financial news reporting (2020-2025)
Factors with Lower Predictive Power Today
Reimbursement: More Critical Than Ever
Payer, CMS, and value-based care arrangements are now fully integrated into diligence. Devices that secure not only coding but also favorable coverage policies and fit into new care delivery models (e.g., hospital-at-home) vault to the top of buyer shortlists.
Example: Remote monitoring device companies with established CMS coverage under RPM/CCM codes in the US routinely sell for double or triple the EV/Sales multiple similar firms still seeking reimbursement clarity.
Valuing Pre-Revenue Companies: Proceed with Caution
Robins’s thesis concluded, and still holds, that pre-revenue company valuations defy reliable modeling. Today, predictive models will still “fail” to forecast dollar values for disruptive or early-stage tech, especially with new digital/hardware hybrids.
Recent Case Examples
Best Practices for 2025 Dealmakers
In Summary:
Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.
